These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 15601631

  • 1. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
    Albain KS.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1801-4. PubMed ID: 15601631
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B, Jeong JH, Anderson S, Wolmark N.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1823-31. PubMed ID: 15601638
    [Abstract] [Full Text] [Related]

  • 3. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 4. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.
    Ludwig Breast Cancer Study Group.
    N Engl J Med; 1989 Feb 23; 320(8):491-6. PubMed ID: 2644533
    [Abstract] [Full Text] [Related]

  • 5. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH, Silverman P, Lasheen W, Meinert J, Siminoff LA.
    Breast Cancer Res Treat; 2007 May 23; 102(3):301-12. PubMed ID: 17033926
    [Abstract] [Full Text] [Related]

  • 6. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep 23; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B, Mouridsen HT, Jensen MB.
    Acta Oncol; 2008 Sep 23; 47(4):662-71. PubMed ID: 18465334
    [Abstract] [Full Text] [Related]

  • 8. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group.
    J Natl Cancer Inst; 2007 Apr 04; 99(7):506-15. PubMed ID: 17405995
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 10. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M.
    J Natl Cancer Inst; 2005 Jan 19; 97(2):116-26. PubMed ID: 15657341
    [Abstract] [Full Text] [Related]

  • 11. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL.
    J Clin Oncol; 2006 Nov 01; 24(31):4956-62. PubMed ID: 17075113
    [Abstract] [Full Text] [Related]

  • 12. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
    Henry NL, Hayes DF.
    J Clin Oncol; 2007 Jun 20; 25(18):2501-3. PubMed ID: 17577024
    [No Abstract] [Full Text] [Related]

  • 13. [A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
    Sack H.
    Strahlenther Onkol; 1995 Jun 20; 171(6):360-1. PubMed ID: 7597623
    [No Abstract] [Full Text] [Related]

  • 14. Evolving concepts in the systemic adjuvant treatment of breast cancer.
    Bonadonna G.
    Cancer Res; 1992 Apr 15; 52(8):2127-37. PubMed ID: 1559216
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 16. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y.
    J Clin Oncol; 2009 Mar 20; 27(9):1368-74. PubMed ID: 19204202
    [Abstract] [Full Text] [Related]

  • 17. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT, Rong TH, Huang ZF, Zeng CG, Long H, Fu JH, Lin P, Wang X, Wang SY, Wang X, Tang J.
    Ai Zheng; 2005 Mar 20; 24(3):327-31. PubMed ID: 15757535
    [Abstract] [Full Text] [Related]

  • 18. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M, German Adjuvant Breast Cancer Group.
    J Clin Oncol; 2005 Nov 01; 23(31):7842-8. PubMed ID: 16258087
    [Abstract] [Full Text] [Related]

  • 19. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
    Panasci LC.
    J Clin Oncol; 2006 May 20; 24(15):2392; author reply 2392. PubMed ID: 16710042
    [No Abstract] [Full Text] [Related]

  • 20. [Prognostic factors in lymph node negative breast cancer].
    Kleeberg UR.
    Strahlenther Onkol; 2002 Jan 20; 178(1):53-4. PubMed ID: 11977395
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.